December 12, 2018
GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
Media
December 06, 2018
Orexo hosts Capital Markets Day today in Stockholm, Sweden
December 05, 2018
CERENIS announces the results of TANGO, a Phase III clinical study evaluating CER-001 in patients with HDL deficiency
December 05, 2018
Program for Oncopeptides Capital Markets Day December 14th, 2018
December 04, 2018
Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH
December 03, 2018
Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting
December 02, 2018
Nordic Nanovector: Single administration Betalutin® is effective and well-tolerated in R/R iNHL patients: 6 month follow-up data presented at ASH
December 02, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
December 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
December 01, 2018
Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting
